Steve Kelsey, M.D., FRCP, FRCPath
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Steve Kelsey, M.D., FRCP, FRCPath
Revolution Medicines, Inc. reported in an 8-K filed June 22, 2026 that Steve Kelsey, M.D., FRCP, FRCPath retired as employment with the Company, effective January 4, 2027. Revolution Medicines, Inc. reported in an 8-K filed June 22, 2026 that Steve Kelsey, M.D., FRCP, FRCPath was appointed senior advisor to the chief executive officer, effective July 1, 2026.
“On June 18, 2026, Steve Kelsey, M.D., FRCP, FRCPath, informed Revolution Medicines, Inc. (the "Company") of his intent to retire from his employment with the Company effective as of January 4, 2027.”
“Dr. Kelsey will transition from his role as the Company's president, research and development to a new position as senior advisor to the chief executive officer effective as of July 1, 2026.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
2026-07-01–2027-01-04
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.